ERBB3 and non-small cell lung carcinoma: In conclusion, the therapeutic activities of cetuximab and trastuzumab can be augmented by adding an anti‐HER3 antibody, such that the oligoclonal mixture of two humanized antibodies and a murine mAb persistently inhibits TKI‐resistant NSCLC models.